^
    Back
    Association details:
    Biomarker:IL2RA expression
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:camidanlumab tesirine (ADCT-301) (DNA replication inhibitor, CD25-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2020
    Title:

    1178 Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models

    Published date:
    11/04/2020
    Excerpt:
    In vivo, camidanlumab tesirine was tested either alone (0.05 or 0.1 mg/kg, single dose) or in combination with gemcitabine (80 mg/kg, q3dx4) in the CD25-expressing ALCL Karpas299 xenograft model. At both ADC dose levels, combination with gemcitabine resulted in synergistic anti-tumor activity (coefficient of drug interaction (CDI) 0.51 and 0.17, respectively), better response rates and increased survival compared to monotherapy with camidanlumab tesirine.
    Secondary therapy:
    gemcitabine